Alnylam Pharmaceuticals
NEWS
Biotech investor Vivek Ramaswamy has launched another company. This time his company, dubbed Genevant, will focus on the development of RNA-based therapies and is the combined product of Roivant Sciences and Arbutus Biopharma Corporation.
Pfizer could be eying the green light for a first-ever regulatory approved treatment for transthyretin cardiomyopathy (TTR) following positive topline results from a late-stage study.
Regeneron Pharmaceuticals and Alnylam Pharmaceuticals signed a collaboration deal to identify RNAi therapies for nonalcoholic steatohepatitis (NASH) and other possibly related liver diseases.
The stock market has been rocky recently, but overall the biotech market appears to have been comparatively stable.
The effort was announced last week by the Henri A. Termeer Tribute Committee.
This not the first time Maraganore has tweeted his support for the benefits of immigration.
The possibility of a tax bill being passed has many investors and analysts forecasting 2018 to be a big year for mergers and acquisitions.
Boston Business Journal pulled together a list of the 25 biggest gainers in the state for 2017, and five of them are biopharma companies.
JOBS
IN THE PRESS